– Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 – – Advanced IND-enabling studies for MM-402 with the Phase 1 investigator-initiated pharmacokinetic/pharmacodynamic trial on track to initiate in Q3 2022 – – Appoints Drs. Suzanne Bruhn and Roger Crystal as independent members of the Board of Directors…


Previous articleCan Psilocybin Treat Obesity? New Evidence, Future Directions
Next articlePT346 – Kevin Balktick – Horizons Northwest, The Psilocybin Services Act, and the Magic in Gathering Together